An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

Trials of a new asthma drug show that it could prove life changing for many people – who would only need two jabs a year. The ...

A twice-yearly injection that could prevent thousands of asthma patients from suffering life-threatening attacks will go on ...

Analysis finds those from most deprived backgrounds almost twice as likely to be admitted to hospital for respiratory conditions ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

For the millions of Australians living with asthma or seasonal allergies, summer isn't just about making the most of long, ...

A former Scottish Government minister has spoken out about his support for assisted dying – even though he says he does not ...

Holidays are a time of joy and fun, but for some they are also associated with a number of health risks. Often during this ...

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document for ...